Longevity Startup Funding 2025-2026

What are all the funding deals in the longevity market from June 2025 to May 2026?

The table below lists every disclosed equity round raised by pure-play longevity companies between June 2025 and May 2026. We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how longevity fits inside the broader healthspan and aging opportunity, we cover it in our Longevity market report.

How active has fundraising been in the longevity market?

As of May 2026, fundraising in the longevity market has been visible but not yet broad. Over the past 12 months, companies raised 16 disclosed equity rounds and $708.6M combined, which works out to 1.33 deals per month.

The activity level is meaningful for a young market, but it is not deep enough to call the longevity market liquid. The median month had just one disclosed deal, and September 2025, April 2026, and May 2026 had no qualifying rounds in the dataset.

Dollar flow looks larger than the underlying cadence. Average capital raised per month was $59.05M, but the median month was only $25.00M, which is a better guide to a normal month.

Removing rounds above $50M changes the picture sharply. Capital raised outside those large rounds totals $195.6M, so the routine funding base in the longevity market is far smaller than the headline total suggests.

If you’re interested in knowing more about the top startups in this industry, check our market report covering longevity companies.

How concentrated has fundraising been in the longevity market?

As of May 2026, fundraising in the longevity market is highly concentrated at the top. Over the past 12 months, the single largest deal accounts for 42.05% of all capital raised, the top 3 deals reach 64.63%, and the top 5 reach 78.75%.

Function Health alone raised $298.0M, which makes it the main driver of the market’s dollar total. That one round is larger than every other category except Longevity Therapeutics Developers and Preventive Health Platforms themselves.

The top 10 deals account for 95.19% of disclosed capital in the longevity market. That leaves only 4.81% of dollars for the bottom six rounds, even though those rounds still matter for company formation.

This concentration means the headline funding total should not be read as broad category momentum. It is better read as a small number of investors making large commitments to a few companies with clearer distribution, data, clinical, or therapeutic paths.

How much of the longevity funding signal is driven by outliers?

As of May 2026, a large share of the funding signal in the longevity market is driven by outliers. Over the past 12 months, four rounds above $50M captured $513.0M, or 72.40% of all disclosed capital.

Only one round was strictly above $100M: Function Health’s $298.0M Series B. That single round explains why the market’s average round size is $44.29M, while the median round size is only $19.0M.

The outlier pattern also appears in monthly totals. November 2025’s capital total comes entirely from Function Health, so any claim about late-2025 acceleration needs to be tested against deal breadth, not just dollars.

A useful reading rule is to separate market proof from company proof. The longevity market has several credible companies, but the funding total is still heavily dependent on a few companies proving they can scale beyond niche longevity buyers.

Is the longevity market broad with many targets, or narrow with few fundable companies?

As of May 2026, the longevity market is narrow rather than broad. Only 15 unique companies produced 16 disclosed equity rounds over the past 12 months, which means the investable pure-play universe remains thin.

The market does show category diversity. The dataset includes therapeutics, diagnostics, clinics, preventive platforms, and consumer longevity brands, so investor interest is not confined to one product form.

But the number of fundable targets is still limited. Healthy Aging Clinics produced the most deals with 5 rounds, while Consumer Longevity Brands produced 4, Longevity Therapeutics Developers produced 3, and both Preventive Health Platforms and Diagnostics Biomarker Companies produced only 2 each.

The absence of Aging Research Platforms from the final disclosed dataset is also telling. Investors funded translational products, care delivery, diagnostics, protocols, and therapeutics, but not standalone aging-research infrastructure during this window.

Is longevity mostly an early-stage formation market or a late-stage scaling market?

As of May 2026, the longevity market is mostly early-stage by label but not a broad seed-formation market. Over the past 12 months, early-stage capital, defined as Seed, Series A, Series B, and Unknown, represented $512.1M, or 72.27% of disclosed capital.

That early-stage figure needs interpretation. Series B alone accounts for $371.0M, or 52.36% of total capital, so most early-stage dollars are not true company-formation capital.

Seed rounds tell a different story. Seed deals represent 4 of 16 rounds, or 25.00% of activity, but only $33.0M, or 4.66% of capital. Formation is happening, but investors are not yet writing large first checks across the category.

Late-stage capital is smaller but still important. Series C, Series D+, and Growth Equity together account for $196.5M, or 27.73% of disclosed capital, led by Loyal, Blueprint, and L-Nutra.

If you want to learn more about what investors are currently betting on, check out our report on the longevity market.

Which categories attract the most investor attention in longevity?

As of May 2026, Healthy Aging Clinics attract the most deal-count attention in longevity, while Preventive Health Platforms attract the most capital. Over the past 12 months, clinics produced 5 of 16 deals, but preventive platforms captured $328.0M, or 46.29% of disclosed dollars.

Preventive Health Platforms have only 2 deals, but the category is large because Function Health raised $298.0M and Hone Health raised $30.0M. Investors appear willing to pay more for scalable data, testing, and AI-enabled prevention platforms.

Longevity Therapeutics Developers rank second by capital, with $200.0M and 28.22% of the total. NewLimit, Aeovian, and Loyal show that mechanism-led and regulated longevity bets can still attract institutional-size checks.

Consumer Longevity Brands sit in the middle of the market. They account for 4 deals and $118.2M, suggesting real interest, but less conviction than preventive platforms or therapeutic developers.

Which categories attract disproportionately large checks in the longevity market?

As of May 2026, Preventive Health Platforms attract disproportionately large checks in the longevity market. Over the past 12 months, they represented only 12.50% of deals but 46.29% of capital, creating a capital-share to deal-share ratio of 3.70x.

This outsized ratio is mostly a Function Health effect, but the implication is still important. Investors seem to value platforms that combine testing, health records, scans, wearables, and AI into a recurring prevention layer.

Longevity Therapeutics Developers also attract above-average check sizes. Their capital-share to deal-share ratio is 1.51x, supported by Loyal’s $100M Series C, Aeovian’s $55M Series B, and NewLimit’s $45M financing.

Healthy Aging Clinics show the opposite pattern. They have the highest deal count but only a 0.19x capital-share to deal-share ratio, which suggests service-heavy clinic models raise smaller checks even when demand is credible.

Which geographies matter most for fundraising in the longevity market?

As of May 2026, North America is the geography that matters most for longevity fundraising. Over the past 12 months, it captured $685.5M, or 96.74% of disclosed capital, from 11 of the 16 deals.

North America’s lead is not only about deal count. The region’s average round size is $62.32M, and its median round size is $45.0M, which is far above every other region in the dataset.

Asia-Pacific produced 4 deals, or 25.00% of activity, but only $14.4M, or 2.03% of capital. That suggests APAC longevity entrepreneurship is emerging, but not yet financed at North American venture levels.

Europe appears through one disclosed round: GlycanAge’s $8.7M financing. The round shows scientific credibility in aging biomarkers, but Europe did not contribute a broad pure-play longevity financing base during the period.

If you want to identify the opportunities currently emerging in this market, explore our market pitch on longevity.

Is the longevity opportunity set broad or concentrated in one hub?

As of May 2026, the longevity opportunity set is concentrated in one financing hub. North America holds 96.74% of disclosed capital and 68.75% of disclosed deals over the past 12 months.

Asia-Pacific is visible on deal count, but its dollar weight is small. The region produced 4 deals with an average round size of $3.60M and a median of $2.85M.

Europe is present but thin. Its single disclosed qualifying deal gives it 6.25% of deal count and 1.23% of disclosed capital in the longevity market.

Latin America, the Middle East, and Africa produced no qualifying pure-play disclosed equity deals in the dataset. That does not mean there is no demand for longevity products there, but it does show that public venture financing is not yet geographically broad.

Is longevity a market of small experiments or scaled financings?

As of May 2026, longevity is a mixed market with both small experiments and a few scaled financings. Over the past 12 months, 3 deals were below $5M, 5 were between $5M and $20M, 4 were between $20M and $50M, and 4 were above $50M.

The median round size is $19.0M, which points to a market where many companies are still proving commercial repeatability. That is very different from the average round size of $44.29M, which is pulled upward by a small number of large rounds.

Rounds above $50M are only 25.00% of deal count, but they account for 72.40% of capital. In other words, the longevity market still has many experimental checks, but its dollar narrative is controlled by scaled financings.

The best interpretation is that the market is bifurcated. Clinics, diagnostics, and consumer brands often raise modest rounds, while preventive platforms and regulated therapeutic paths can absorb much larger amounts of capital.

If you want to stay on top of the latest trends, risks, and opportunities in this market, check out our market report on longevity, updated every quarter.

Who are the investors that appear the most in longevity fundraising?

As of May 2026, repeat investor patterns in the longevity market are limited. Over the past 12 months, no confirmed institutional investor made more than one cross-company qualifying deal in the final dataset.

The clearest repeat pattern is NKSquared or Nikhil Kamath-linked capital across Biopeak financings. That includes participation reported around the June 2025 seed and the January 2026 follow-on led by NKSquared.

Most other named investors appear in one qualifying company each. Khosla Ventures, age1, Redpoint, Prelude Growth, Mubadala, Accel, Luma Group, CTI Life Sciences, Tidal Ventures, and others show up as single-company backers during the strict window.

This matters because the longevity market does not yet look like a standardized allocation category for generalist venture portfolios. It still behaves like a specialist-conviction market where investors choose specific theses rather than buying broad exposure.

One caveat is important: round announcements rarely disclose how much each investor personally committed. Any investor ranking in the longevity market should therefore be read as participation evidence, not exact dollars deployed by investor.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.